Form 10-Q · Quarterly report
Equifax 10-Q, filed Oct 20, 2026
- Filed
- CIK
- 0000033185
- Accession no.
- 0000033185-26-000044
Summary
Equifax reported third-quarter 2026 operating revenue of $1.69 billion, up 10% from a year earlier, with net income attributable to Equifax of $211.7 million and diluted earnings per share of $1.79, up from $1.29. The company said its current planning for 2026 assumes U.S. GDP growth consistent with 2025 while U.S. mortgage origination activity runs below 2025 levels, and it noted continued uncertainty over inflation and interest rates.
Key points
- Nine-month 2026 operating revenue was $5.04 billion, up 11% year over year, with operating income of $957.2 million and diluted EPS of $4.75.
- Third-quarter revenue rose in all three segments: Workforce Solutions +7% to $693.9 million, U.S. Information Solutions +13% to $599.1 million, and International +9% to $399.5 million.
- Equifax's board approved an increase in the quarterly cash dividend to $0.56 per share beginning in the first quarter of 2026; the company paid $199.4 million, or $1.68 per share, in dividends in the first nine months of 2026.
- Equifax repurchased 3,640,019 shares for $652.0 million in the first nine months of 2026, leaving about $1.4 billion available under its $3 billion buyback authorization.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION BUSINESS OVERVIEW Equifax Inc. is a global data, analytics and technology company. We provide information solutions for businesses, governments and consumers, and we provide human resources business process automation and outsourcing services for employers. We have a large and diversified group of clients, including financial institutions, corporations, government agencies and individuals. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.